2023 Q4 Form 10-Q Financial Statement

#000095017023062011 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $36.28M $11.99M
YoY Change 167.26% -9.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $116.5M $29.40M
YoY Change 393.09% 32.76%
% of Gross Profit
Research & Development $435.1M $113.7M
YoY Change 334.92% 17.64%
% of Gross Profit
Depreciation & Amortization $2.466M $2.290M
YoY Change 21.42% 17.44%
% of Gross Profit
Operating Expenses $551.6M $113.7M
YoY Change 346.03% 17.64%
Operating Profit -$131.1M
YoY Change 24.24%
Interest Expense $34.20M $8.880M
YoY Change 1523.88% 7900.0%
% of Operating Profit
Other Income/Expense, Net -$100.0K $8.883M
YoY Change -98.16% -215.38%
Pretax Income -$481.2M -$122.2M
YoY Change 324.31% 7.94%
Income Tax
% Of Pretax Income
Net Earnings -$481.2M -$122.2M
YoY Change 324.31% 7.94%
Net Earnings / Revenue -1326.51% -1019.21%
Basic Earnings Per Share -$1.38
Diluted Earnings Per Share -$5.42 -$1.38
COMMON SHARES
Basic Shares Outstanding 89.55M 88.49M
Diluted Shares Outstanding 88.65M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $912.2M $854.8M
YoY Change -23.51% 3.21%
Cash & Equivalents $226.7M $168.0M
Short-Term Investments $685.5M $686.8M
Other Short-Term Assets $49.65M $32.20M
YoY Change 143.3% 20.46%
Inventory
Prepaid Expenses
Receivables $36.46M $6.491M
Other Receivables $0.00 $0.00
Total Short-Term Assets $998.3M $893.5M
YoY Change -17.95% 4.02%
LONG-TERM ASSETS
Property, Plant & Equipment $32.76M $33.80M
YoY Change 17.33% 27.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $11.77M $17.17M
YoY Change -63.75% -57.19%
Other Assets $42.88M $42.40M
YoY Change 5.81% 14.63%
Total Long-Term Assets $302.6M $349.9M
YoY Change -0.22% 55.14%
TOTAL ASSETS
Total Short-Term Assets $998.3M $893.5M
Total Long-Term Assets $302.6M $349.9M
Total Assets $1.301B $1.243B
YoY Change -14.42% 14.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.452M $3.553M
YoY Change 44.59% -18.96%
Accrued Expenses $67.02M $57.98M
YoY Change 10.09% -0.69%
Deferred Revenue $22.14M $13.35M
YoY Change -49.5% -75.65%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $115.2M $91.95M
YoY Change -8.97% -29.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $135.6M $114.0M
YoY Change -14.16% -11.2%
Total Long-Term Liabilities $135.6M $114.0M
YoY Change -14.16% -11.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $115.2M $91.95M
Total Long-Term Liabilities $135.6M $114.0M
Total Liabilities $250.8M $205.9M
YoY Change -11.85% -20.64%
SHAREHOLDERS EQUITY
Retained Earnings -$1.658B -$1.526B
YoY Change 40.88% 43.47%
Common Stock $2.711B $2.567B
YoY Change 12.01% 35.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.050B $1.037B
YoY Change
Total Liabilities & Shareholders Equity $1.301B $1.243B
YoY Change -14.42% 14.65%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$481.2M -$122.2M
YoY Change 324.31% 7.94%
Depreciation, Depletion And Amortization $2.466M $2.290M
YoY Change 21.42% 17.44%
Cash From Operating Activities -$93.06M -$101.4M
YoY Change 3.55% 29.1%
INVESTING ACTIVITIES
Capital Expenditures $1.515M $4.340M
YoY Change -61.27% -202.43%
Acquisitions
YoY Change
Other Investing Activities $47.46M $83.83M
YoY Change -280.86% 61.58%
Cash From Investing Activities $45.94M $79.50M
YoY Change -252.37% 66.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 106.5M 19.10M
YoY Change -78.95% -20.34%
NET CHANGE
Cash From Operating Activities -93.06M -101.4M
Cash From Investing Activities 45.94M 79.50M
Cash From Financing Activities 106.5M 19.10M
Net Change In Cash 59.37M -2.780M
YoY Change -84.61% -59.75%
FREE CASH FLOW
Cash From Operating Activities -$93.06M -$101.4M
Capital Expenditures $1.515M $4.340M
Free Cash Flow -$94.57M -$105.7M
YoY Change 0.84% 42.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001652130
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37766
dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4785571
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Erie Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 130
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
285-6200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTLA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89554891
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168027000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
523506000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
686761000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
669116000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6491000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3768000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32214000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20407000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
893493000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1216797000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
137752000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
69338000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33800000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27921000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
118775000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
133076000
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
17166000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
32455000
CY2023Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
42363000
CY2022Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
40527000
CY2023Q3 us-gaap Assets
Assets
1243349000
CY2022Q4 us-gaap Assets
Assets
1520114000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3553000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5154000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
57979000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
60876000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17074000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16685000
CY2023Q3 ntla Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
0
CY2022Q4 ntla Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
19900000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13347000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
43839000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
91953000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126554000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12719000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19932000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101263000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
114018000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
24026000
CY2023Q3 us-gaap Liabilities
Liabilities
205935000
CY2022Q4 us-gaap Liabilities
Liabilities
284530000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89097821
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89097821
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87103007
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87103007
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2567195000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2420223000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3572000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7461000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1526218000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1177187000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1037414000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1235584000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1243349000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1520114000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11992000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13266000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38192000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38548000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113696000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96651000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
326088000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319945000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29403000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22145000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
87503000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66680000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
143099000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
118796000
us-gaap Costs And Expenses
CostsAndExpenses
413591000
us-gaap Costs And Expenses
CostsAndExpenses
386625000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-131107000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-105530000
us-gaap Operating Income Loss
OperatingIncomeLoss
-375399000
us-gaap Operating Income Loss
OperatingIncomeLoss
-348077000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12740000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1945000
us-gaap Investment Income Interest
InvestmentIncomeInterest
37373000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3188000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3857000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1834000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10905000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7831000
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
7810000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
8059000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8883000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7699000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26368000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12702000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-113229000
us-gaap Net Income Loss
NetIncomeLoss
-349031000
us-gaap Net Income Loss
NetIncomeLoss
-360779000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.78
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88645000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88645000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76047000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76047000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88204000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88204000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75543000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75543000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
142000
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
991000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1649000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5069000
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
154000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-805000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
2240000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-1667000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121928000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113043000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-345142000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-367515000
CY2023Q3 ntla Revenue From Related Party
RevenueFromRelatedParty
1946000
CY2022Q3 ntla Revenue From Related Party
RevenueFromRelatedParty
4414000
ntla Revenue From Related Party
RevenueFromRelatedParty
12673000
ntla Revenue From Related Party
RevenueFromRelatedParty
15612000
us-gaap Profit Loss
ProfitLoss
-349031000
us-gaap Profit Loss
ProfitLoss
-360779000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6510000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5541000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
162000
us-gaap Share Based Compensation
ShareBasedCompensation
99007000
us-gaap Share Based Compensation
ShareBasedCompensation
66774000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
19590000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5252000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10905000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7831000
us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
6624000
us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
8530000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
8059000
ntla In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
0
ntla In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
55990000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2723000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1992000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11806000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
228000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-14148000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-8516000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
836000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
982000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1419000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5334000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3008000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12852000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37705000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-46739000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-12213000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-6547000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-301032000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-243418000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12465000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9646000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
754689000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
192598000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
689868000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
437387000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
150000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
287000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
44832000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77286000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
190461000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5604000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13984000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2051000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1068000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23839000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77192000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-354479000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24235000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
535463000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125486000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180984000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149721000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168027000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141194000
CY2023Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
12957000
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
8527000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180984000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149721000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1552000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2180000
CY2023Q3 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
24126000
CY2022Q3 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
0
ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
0
ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
30663000
CY2023Q3 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
0
CY2022Q3 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10541000
ntla Proceeds From At The Market Offerings Unpaid At Period End
ProceedsFromAtTheMarketOfferingsUnpaidAtPeriodEnd
0
ntla Proceeds From At The Market Offerings Unpaid At Period End
ProceedsFromAtTheMarketOfferingsUnpaidAtPeriodEnd
8255000
ntla Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
0
ntla Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
200000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
826633000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2167000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
824513000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
742215000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
62000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3823000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
738454000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2022 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
ntla Research Milestone Payments
ResearchMilestonePayments
25000000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
24026000
CY2023Q3 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-24126000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2022 ntla Discount Rate
DiscountRate
0.101
CY2022 ntla Probability Of Achievement
ProbabilityOfAchievement
1
CY2022 ntla Projected Year Of Achievement
ProjectedYearOfAchievement
2023
CY2023Q3 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24241000
CY2022Q4 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
32684000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21006000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21778000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1649000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1457000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11083000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4957000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
57979000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
60876000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3768000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
15287000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
12564000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6491000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63771000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-37705000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
26066000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2031000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
8678000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
6686000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4023000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127235000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-46739000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
80496000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
31081000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
38208000
CY2023Q3 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
ntla Business Combination Upfront Cash Consideration
BusinessCombinationUpfrontCashConsideration
43730000
ntla Business Combination Research Contingent Consideration Liabilities
BusinessCombinationResearchContingentConsiderationLiabilities
10541000
ntla Business Acquisition Cost Of Acquired Entity Transaction Cost
BusinessAcquisitionCostOfAcquiredEntityTransactionCost
1838000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
56109000
CY2023Q3 ntla Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
55990000
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
287000
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
153000
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
321000
CY2023Q3 ntla Business Combination Transaction Price
BusinessCombinationTransactionPrice
56109000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35352000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25215000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99007000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66774000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1941379
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
70.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2774271
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
597610
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
68.31
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
193503
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
49.7
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3924537
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
52.07
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.75
CY2022Q1 ntla Number Of Tranches
NumberOfTranches
2
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
39.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.36
CY2023Q3 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
4200000
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
22500000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
55.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
72.48
CY2022Q3 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
100000
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
8000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.23
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6600000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
41800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.044
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.787
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.762
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5471675
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
569821
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
41
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
319847
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
130474
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
80.2
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5591175
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
50.1
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M13D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39821000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3846015
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6600000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
36370000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
69200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y7M17D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-113229000
us-gaap Net Income Loss
NetIncomeLoss
-349031000
us-gaap Net Income Loss
NetIncomeLoss
-360779000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88645000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88645000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76047000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76047000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88204000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88204000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75543000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75543000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.78
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9516000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9516000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7476000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7476000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
62000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2051000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36400000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1482000
CY2023Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
292000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-123681000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1104888000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
81000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4384000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35352000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
142000
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
154000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1037414000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1040244000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
164000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8435000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18491000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5128000
CY2022Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-302000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-146872000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
953754000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4827000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1068000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23068000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-932000
CY2022Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-560000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-100678000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
880547000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
54000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
722000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25215000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-991000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
-805000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-113229000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
824951000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1000000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
ntla-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062011-index-headers.html Edgar Link pending
0000950170-23-062011-index.html Edgar Link pending
0000950170-23-062011.txt Edgar Link pending
0000950170-23-062011-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img231249033_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
ntla-20230930.htm Edgar Link pending
ntla-20230930.xsd Edgar Link pending
ntla-ex10_1.htm Edgar Link pending
ntla-ex10_2.htm Edgar Link pending
ntla-ex31_1.htm Edgar Link pending
ntla-ex31_2.htm Edgar Link pending
ntla-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
ntla-20230930_def.xml Edgar Link unprocessable
ntla-20230930_lab.xml Edgar Link unprocessable
ntla-20230930_pre.xml Edgar Link unprocessable
ntla-20230930_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending